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Abstract
Background: Vitamin D deficiency is highly prevalent in dialysis patients. Whether substitution of native vitamin D
in these patients is beneficial is a matter of ongoing discussion, as is the optimal dosing schedule. The purpose of
this study was to investigate the efficacy and safety of a body-weight adapted oral dosing regimen of cholecalciferol in
dialysis patients.
Methods: In a prospective single-center study 56 prevalent dialysis patients with a baseline 25OHD3 level <20 ng/mL
received 100 IU of cholecalciferol per kg body weight once weekly orally for 26 weeks. 25OHD3 was measured at
baseline and at study end, iPTH every three months, serum calcium and phosphorous monthly. Concurrent medication
including phosphate binders, calcitriol and cinacalcet and dialysate calcium concentration remained unchanged
throughout the study.
Results: Baseline 25OHD3 was 9.9 ± 4.1 ng/mL and increased to 26.1 ± 8.8 ng/mL (P = 0.01). Fourteen patients (27 %)
achieved a level >30 ng/mL and all others above 20 ng/mL. Cinacalcet therapy was positively associated with the
increase in 25OHD3 (P = 0.024). The plasma iPTH level significantly decreased from median 362 pg/mL to 297 pg/mL
(P = 0.01). This decline was more pronounced in patients with higher baseline iPTH levels (P < 0.01) and differed
significantly dependent on concurrent calcitriol therapy. A significant iPTH decrease was observed in patients receiving
calcitriol (P = 0.031). Serum calcium and phosphorous did not change significantly throughout the study period.
Cholecalciferol substitution was well tolerated without adverse effects.
Conclusion: The dosing regimen of oral cholecalciferol supplementation with 100 IU per kg body weight per week for
26 weeks in dialysis patients with vitamin D deficiency causes a significant increase in 25OHD3 close to the supposed
target level of 30 ng/mL and a significant reduction in iPTH, without affecting serum calcium or phosphorous levels.
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Background
Vitamin D deficiency affects about one billion people
worldwide. It is especially prevalent at higher altitudes,
where sun exposure is low [1]. In Germany, 58 % of men
and 57 % of women have 25-hydroxy-vitamin D3
(25OHD3) levels below 20 ng/mL, the most current def-
inition of vitamin D deficiency [2]. Vitamin D deficiency
has been found to be associated with a multitude of
diseases such as cancer, cardiovascular disease, diabetes
and autoimmunity [1]. A recent umbrella review of sys-
tematic reviews and meta-analyses of observational stud-
ies and randomized trials comes to the conclusion that
among 137 outcomes vitamin D supplementation affects
only birth weight, dental caries in children and parathy-
roid hormone (PTH) concentrations in patients with
chronic kidney disease [3]. The authors conclude that
current evidence suggests vitamin D supplementation
only for pregnant women, children and for CKD patients
with and without dialysis with the goal of lowering PTH
levels. The results of this umbrella analysis, however, are
based on a meta-analysis of active vitamin D compounds
in dialysis patients [4]. With regard to substitution of
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native vitamin D in CKD patients, such data are not
available, because no large randomized controlled trials
have been performed. Nevertheless, recommendations
issued by NKF KDOQI, KDIGO and the European Best
Practice Group guidelines, support correction of vitamin
D deficiency in CKD patients [5–7]. However, only the
KDIGO guidelines suggest supplementation in dialysis
patients [6]. Concerning dose, treatment strategies used
for the general population are recommended. Most
studies addressing treatment of vitamin D deficiency in
dialysis patients use weekly doses of 50.000 IU ergocal-
ciferol or cholecalciferol, as recommended by KDOQI
for the general population and for patients with CKD
stage 3 to 4 [1, 5]. The lowest weekly doses reported in
the literature in hemodialysis patients are 4500 IU
(640 IU daily), 10.000 IU (40.000 IU monthly) and
10.333 IU cholecalciferol [8–10]. At a consensus meet-
ing held in August 2012 experts from Germany, Austria
and Switzerland recommended treatment of vitamin D
deficiency with 70 to 140 IU cholecalciferol per kilo-
gram body weight per week to increase 25OHD3 levels
by 10 ng/mL (Pharma Report, Der Internist, 54(2),
2013). These recommendations were recently con-
firmed in a systematic review of vitamin D supplemen-
tation, body weight and serum 25OHD3 response [11].
The aim of the present study was to determine the
efficacy of a dosing regimen of 100 IU of cholecalciferol
per kg per week, over a period of six months in preva-
lent dialysis patients and to describe its effects on serum
calcium, serum phosphorous and plasma iPTH.
Methods
We prospectively included prevalent adult hemodialysis
and peritoneal dialysis patients with a serum 25OHD3
level <20 ng/mL as determined in December 2012. Indi-
viduals with a serum calcium >2.55 mmol/L or serum
phosphorous >2.50 mmol/lL, or patients unable to give
informed consent were excluded. This was a single-
center study performed at the Academic Teaching Hos-
pital Feldkirch in Feldkirch (Austria) at latitude 47.23°
North. Patients were given oral cholecalciferol (Oleovit
D3 Tropfen®, Fresenius Kabi, Graz, Austria, 400 IU per
drop) 100 IU per kg body weight once weekly. Treatment
was started in June 2013 and continued for 26 weeks until
December 2013. Hemodialysis patients received the drop-
lets at the end of the first dialysis section of the week. Peri-
toneal dialysis patients were advised to take the prescribed
dose once per week at home. The dose of phosphate
binders, calcitriol and cinacalcet was held constant during
the study period. The dialysate calcium concentration was
1.25 mmol/L in all patients and was kept unchanged
throughout the study. Retrospectively, 25OHD3 levels
measured in December 2011 were collected and com-
pared to evaluate the random variability of 25OHD3 levels
without cholecalciferol substitution (December 2011 to
December 2012).
The following demographic, anthropometric, clinical
and medical parameters were collected at study entry: age,
sex, height, body weight (dry weight), renal disease, treat-
ment and dose of calcitriol, cinacalcet, and phosphate
binders. Serum calcium and phosphorous were measured
monthly, plasma iPTH every three months. The investiga-
tion was registered with AGES (Austrian Agency for
Health and Food Safety, registration number NIS002983)
as a non-interventional study without any interventions or
investigations beyond routine patient management. Single
center non-interventional studies do not require ethical
approval by Austrian law. The study was performed in
agreement with the Declaration of Helsinki and Austrian
law. All participating patients gave written informed con-
sent to participate in the study.
Statistical analysis
Continuous data are presented as mean ± SD or median
(25th, 75th percentile) dependent on the distribution of the
variables, categorical variables as absolute and relative fre-
quencies (%). Normal distribution was evaluated with the
Kolmogorov-Smirnov test. Levels of 25OHD3, iPTH, cal-
cium and phosphorous before and after cholecalciferol
supplementation were compared using the paired T test
(Ca, P) or the Wilcoxon rank sum test (iPTH). Group
differences were determined by ANOVA for continuous
variables and by chi-square test or Fisher exact test for
categorical variables as appropriate. Multiple linear regres-
sion models were applied to assess predictors of 25OHD3
and iPTH response with cholecalciferol supplementation.
A P value less than 0.05 (two-sided) was deemed to indi-
cate statistical significance. All statistical analyses were
performed with IBM SPSS Statistics, version 22 (SPSS
Inc., Chicago, IL).
Results
Fifty-six patients, 44 on hemodialysis and 12 on periton-
eal dialysis, with a mean age of 63 ± 18 years were in-
cluded out of 82 screened patients. Of those entering
the study 29 (52 %) were men and 27 (48 %) were
women. Fifty-one patients (91 %) completed the study.
Three patients died during the study, one received a kid-
ney transplant and one moved to another dialysis unit.
Causes of death were cardiac arrest, advanced breast
cancer and sepsis, none of them suspected to be linked
to the cholecalciferol substitution (Fig. 1).
Baseline characteristics of participating patients are
listed in Table 1. Results for 25OHD3, serum calcium,
phosphorous and plasma iPTH before and after 26 weeks
of cholecalciferol substitution are shown in Table 2. Mean
25OHD3 had been 9.0 ± 4.1 ng/mL in December 2011
(one year prior to the evaluation of the pre-supplemental
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concentration) and remained unchanged in December
2012 without substitution (9.9 ± 4.1 ng/mL). Patients
received a mean weekly cholecalciferol dose of 7603 ±
1855 IU. After six months of substitution 25OHD3
increased to 26.1 ± 8.8 ng/mL (P < 0.01) with a mean in-
crease of 16.2 ± 7.8 ng/mL. At the end of the study 14
(27 %) patients had a 25OHD3 level >30 ng/mL, and all 37
(73 %) other patients a level >20 ng/mL. Serum calcium
and phosphorous remained constant. Figure 2 shows the
course of monthly serum calcium and phosphorous levels
during the whole study period. We observed six hypercalce-
mic episodes (serum calcium >2.55 mmol/L) representing
1.9 % of all monthly measurements (n = 306). Hypercalce-
mia was noted in four patients (three patients with one
episode, one patients with three episodes). A total of 13
episodes (4.2 %) of hyperphosphatemia (serum phos-
phorus >2.50 mmol/L) occurred during the whole study
period in nine patients (five patients with one episode,
4 patients with two episodes). Table 3 shows the results
of the multiple linear regression analysis for the 25OHD3
increase. Use of cinacalcet (P = 0.024) and hemodialysis
versus peritoneal dialysis treatment (P = 0.045) was signifi-
cantly associated with a better response to cholecalciferol
substitution.
As shown in Fig. 3, iPTH levels decreased from median
362 pg/mL (258, 498) to 297 (202, 434) pg/mL (P = 0.01)
during the treatment period. The only significant pre-
dictor of iPTH reduction was baseline iPTH with a greater
decrease observed in patients with higher baseline values
(Table 4). Patients who were under calcitriol treatment
showed a greater iPTH response to cholecalciferol as
compared to those without calcitriol (Fig. 4).
Discussion
Whether individuals with and without kidney disease
suffering from vitamin D deficiency need vitamin D sub-
stitution and how this substitution should be given are
matters of debate. When determining the optimal vita-
min D dose it is crucial to understand the kinetics of
conversion of vitamin D to 25OHD3. At present, the
exact liver enzyme or enzymes for 25-hydroxylation are
still unknown, but the most likely candidates are
CYP2R1, CYP3A4 and CYP27A [12–14].
Heaney described a biphasic pattern of 25-hydroxylation.
At low doses of cholecalciferol the compound is com-
pletely converted to 25OHD3, meaning that cholecalciferol
concentrations remain low and 25OHD3 serum concentra-
tions rise rapidly [15]. When daily cholecalciferol doses
above 2000 IU are given, the enzymes become saturated,
serum cholecalciferol rises and some of it is stored in fat
tissue, and 25OHD3 serum levels continue to rise slowly.
The 25OHD3 breakpoint of this biphasic response is at
about 35 ng/mL, which is practically identical to the level,
below which PTH levels begin to rise in response to low
25OHD3 levels [16]. This study clearly explains why
25OHD3 increases rapidly under low doses of cholecalcif-
erol and that supraphysiologic doses above 2000 UI per
day cause an only marginal further increase. Although
these results were obtained in healthy individuals, there is
no reason to believe that CKD patients would behave dif-
ferently. In fact, published studies of cholecalciferol substi-
tution in CKD and hemodialysis patients are in line with
this observation [9, 10, 17–22].
We are not aware of any study in dialysis patients inves-
tigating a body weight-based oral cholecalciferol dosing
Fig. 1 Patient flow diagram
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regimen. Body weight is the most important determinant
of the 25OHD3 response to a given cholecalciferol dose
[11, 23]. This phenomenon may be partly explained by the
fact that in patients with higher body weight and more
body fat an increasing proportion of administered vita-
min D is stored in fat tissue and not available for 25-
hydroxylation [24]. Earlier studies with oral vitamin D2
(ergocalciferol) supplementation have shown an inverse
correlation between peak serum vitamin D2 levels and
body-mass-index or obesity, respectively [24] . In older
Table 1 Baseline characteristics of patients
Gender
Men 29 (52 %)
Women 27 (48 %)
Age (years) 63 ± 18
Body Weight (kg) 76 ± 19
Dialysis vintage (months) 46 (24,63)
Renal disease
Diabetic nephropathy 16 (29 %)
Hypertensive nephropathy 10 (18 %)
Glomerulonephritis 13 (23 %)
Polycystic kidney disease 4 (7 %)
Interstitial nephritis 1 (2 %)
Other 12 (21 %)
Diabetes mellitus 19 (34 %)
Vascular access
AV fistula 30 (77 %)
AV graft 5 (13 %)
Catheter 4 (10 %)
Creatinine (mg/dl) 8.2 ± 2.9
Urea (mg/dl) 125 ± 34
Albumin (g/dl) 3.5 ± 0.3
Hemoglobin (g/l) 111 ± 12.6
Calcitriol 40 (71 %)
Dose per day (μg) 0.26 ± 0.10
Treatment vintage (months) 34 (19, 51)
Ca-containing PB 20 (36 %)
Treatment vintage (months) 29.5 (8.3, 57.5)
Ca-free PB 24 (43 %)
Treatment vintage (months) 30.5 (19.5, 48.5)
Cinacalcet 26 (46 %)
Dose per day (mg) 52 ± 26
Treatment vintage (months) 33 (15.5, 57.5)
Abbreviations: Ca, calcium; PB, phosphate binder. Data are presented as
mean ± SD or median (25th percentile, 75th percentile)
Table 2 25OHD3, calcium, phosphorous and iPTH before and
after cholecalciferol substitution
Baseline After 26 weeks P value
25OHD3 (ng/mL) 9.9 ± 4.1 26.1 ± 8.8 <0.01
Calcium (mmol/L) 2.20 ± 0.16 2.22 ± 0.17 0.45
Phosphate (mmol/L) 1.80 ± 0.45 1.73 ± 043 0.31
iPTH (pg/mL)a 362 (258, 498) 297 (202, 434) 0.01
amedian (25th, 75th percentile)
Fig. 2 Course of serum calcium (a) and phosphorous (b) over
26 weeks of cholecalciferol supplementation. BL, baseline; M1-M6,
months 1–6
Table 3 Multiple linear regression analysis for 25OHD3 increase
(ng/mL) with cholecalciferol supplementation
Parameter Β (95 % CI) P
Age (years) 0.06 (−0.06, 0.17) 0.347
Male gender (vs female) 3.30 (−0.82, 7.42) 0.113
Dialysis mode 0.045
Peritoneal dialysis −5.01 (−9.89, −0.12)
Hemodialysis Ref.
Calcitriol therapy 0.637
Yes 1.07 (−3.46, 5.59)
No Ref.
Cinacalcet therapy 0.024
Yes 4.89 (0.66, 9.13)
No Ref.
Covariates in the model included: age, gender, dialysis mode, calcitriol
therapy, cinacalcet therapy
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(≥64 years) healthy persons, but not in younger adults
(20–40 years) a significant negative association between
baseline 25OHD3 and BMI or adiposity was found.
When these persons were supplemented in a random-
ized placebo-controlled trial (cholecalciferol 600 IU/day
vs placebo), the 25OHD3 response to supplemental
cholecalciferol was negatively associated with baseline
BMI (the mean adjusted change in 25OHD3 decreased
by approximately 2.6 ng/mL with every 5 kg/m2 in-
crease in BMI) [25]. Therefore, we believe that the
body-weight adapted supplementation should not be
adjusted to lean body weight and might possibly be
even more precise when corrected for BMI or fat mass.
This very interesting point should be further investi-
gated in future studies, ideally with quantifying the vita-
min D content in adipose tissue.
Van Groningen calculated the loading dose of cholecal-
ciferol needed to reach a 25OHD3 level of 30 ng/mL using
the formula IU = 100 x (30-25OHD3) x kg BW. Using this
formula, the mean dose for our patients would have been
152.000 IU or a weekly dose of 5850 IU for 26 weeks [23].
In a recent meta-analysis Zittermann et al. showed an ex-
ponential dose requirement when trying to achieve higher
25OHD3 levels [11]. They found a logarithmic association
between cholecalciferol dose per kg body weight and the
increment in 25OHD3. For a 70-year-old person with a
body weight of 75 kg the calculated daily dose to achieve a
target of 20 ng/mL was 308 IU and for a target of 30 ng/
mL the daily dose was 1460 IU (corresponding to a weekly
dose of 10.220 IU). The weekly dose we used based on the
recommendation of 100 IU per kg body weight lies
between these calculated doses. There are other studies of
comparable vitamin D doses in dialysis patients. Armas
et al. used a weekly cholecalciferol dose of 10.333 IU in
twenty patients for 15 weeks. Serum 25OHD3 increased
by 23.6 ng/mL [9]. Jean et al. tested a mean daily dose of
640 IU (400–1200 IU) in 149 hemodialysis patients over
six months [10]. They found an impressive increase in
25OHD3 of 38.4 ng/mL. This favorable result compared
to ours and that of Armas et al. may be explained by the
use of daily low doses as compared to weekly higher doses.
These frequent low doses possibly allow for more quanti-
tative 25-hydroxylation in the liver [15]. These and our
study clearly show that these rather low doses are effective
for reaching 25OHD3 levels at or close to the target range
of 30 ng/mL. From these data we do not believe that daily
doses in excess of 3.500 IU are necessary to correct vita-
min D deficiency in dialysis patients, as recently suggested
[26]. Of note, these dose recommendations apply only to
cholecalciferol and not to ergocalciferol treatment. As
ergocalciferol seems to be less effective in increasing
25OHD3 levels, higher doses may be required when using
vitamin D2 [27]. Although the optimal 25OHD3 level for
CKD and dialysis patients is unknown, a target of 30 ng/
mL may be reasonable for maximal PTH suppression.
Using our dosing regimen the mean 25OHD3 level was
26 ng/ml, but only a minority of patients achieved the
30 ng/mL goal. Therefore, it may be necessary to increase
the weekly dose especially in those patients with very low
basal levels [23]. Keeping in mind the ongoing debate
about erythropoietin and iron therapy in dialysis patients,
we are cautious about recommendations of high and
unphysiological cholecalciferol or ergocalciferol doses. It
may be wise to use the lowest possible vitamin D dose to
achieve a (yet to be clearly defined) 25OHD3 target level.
In our study cinacalcet therapy was associated with a
higher increase in 25OHD3. This association has not
been described until now. Cinacalcet has been shown to
reduce FGF-23 levels in dialysis patients independently
from its effect on iPTH [28–30]. In animal models, FGF-
23 induces expression of CYP24A1 or 24-hydroxylase in
the liver [31, 32]. It could be speculated that induction
Fig. 3 Course of plasma iPTH over 26 weeks of cholecalciferol
supplementation. BL, baseline; M3, month 3; M6, month 6. iPTH
decreased significantly from 362 to 297 pg/mL (P = 0.01)* after
26 weeks of cholecalciferol substitution
Table 4 Multiple linear regression analysis for ΔiPTH (iPTH post-
iPTH pre) (pg/mL) with cholecalciferol supplementation
Parameter Β (95 % CI) P
Age (years) −2.41 (−5.18, 0.37) 0.088
iPTH pre (pg/mL) −0.56 (−0.80, −0.32) <0.001
Δ25(OH)vitamin D (ng/mL) −3.61 (−10.65, 3.42) 0.307
Calcitriol 0.215
Yes −70.39 (−183.22, 42.45)
No Ref.
Cinacalcet 0.483
Yes 37.59 (−69.38, 144.56)
No Ref.
Abbreviations: iPTHpre, iPTH level before cholecalciferol substitution; iPTHpost,
iPTH level after cholecalciferol substitution; Δ25(OH)vitamin D, absolute
change in 25(OH)D3 with cholecalciferol substitution. Covariates in the model
included: age, baseline iPTH, absolute change in 25(OH)D, calcitriol therapy,
cinacalcet therapy
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of CYP24A1 by FGF-23 would lead to enhanced 24-
hydroxylation of 25OHD3 to 24,25OHD3, the first step
in 25OHD3 catabolism and therefore contribute to vita-
min D deficiency in CKD. However, 24,25OHD3 levels
have been found to be rather low in this group of
patients despite elevated FGF-23 [32–34]. Nevertheless,
we speculate that reduction of FGF-23 and consecutive
decrease of CYP24A1 activity and 24-hydroxylation can
explain our observation. Clearly, further studies are
needed to confirm this finding and mechanism in dialy-
sis patients.
The lower response in peritoneal dialysis patients is
most likely explained by lower compliance with home-
based intake than in hemodialysis patients, who were
given their medication at the dialysis ward resulting in a
100 % compliance rate.
A still unresolved question is the optimal 25OHD3 tar-
get level for CKD and dialysis patients. The recent
report from the Institute of Medicine states that a
25OHD3 serum level of 16 ng/mL covers the require-
ments of half the general population and a level of
20 ng/mL of 97.5 % of the population [35]. According to
the umbrella review by Theodoratou et al. a lowering of
PTH is the only indication for vitamin D substitution in
CKD and hemodialysis patients. These data, however, are
based on studies using mainly active vitamin D com-
pounds [4, 36]. There were no other health-related effects
of vitamin D therapy in this population. In agreement with
these findings, a recent small study in hemodialysis
patients also showed no positive effects of cholecalciferol
substitution on muscle strength, functional capacity,
quality of life and pulse wave velocity [37]. Active vitamin
D therapy lowers PTH by 19.7 pg/mL (95 % CI 34.3-5.2)
in CKD patients not on dialysis and by 78.4 pg/mL (119.4-
37.1) in dialysis patients [3]. Since PTH levels increase, at
least in the general population, as serum 25OHD3 drops
below 30 ng/mL, we suggest that this would be the appro-
priate target level for CKD and dialysis patients. A very
recent publication, however, suggests that this level might
be too low for CKD stage 3 to 5 patients, and that a
maximum effect on PTH requires levels between 42 to
48 ng/mL [38]. The central question is whether, as shown
for active vitamin D compound, native vitamin D is also
able to lower PTH levels. We observed a significant de-
cline in PTH levels in our patients. A significant decline in
PTH has not been uniformly found in studies of vitamin
D substitution in CKD patients. In general, patients in
studies without a significant PTH response had iPTH
levels below 200 pg/mL [9, 39, 40], whereas in studies of a
significant PTH decline reported basal levels were above
200 pg/mL [10, 19, 41–43]. This hypothesis is strength-
ened by our observation that baseline PTH is the best pre-
dictor of a PTH decline under cholecalciferol substitution.
Based on our results and the published literature it can be
concluded that native vitamin D substitution in patients
with low 25OHD3 levels is able to cause some PTH reduc-
tion, albeit not to a degree as seen with active vitamin D
compounds. However, the risk of developing hypercalce-
mia or hyperphosphatemia is lower when using native
vitamin D as shown in our study. Recently Armas et al.
found an unchanged calcium absorption despite a high
cholecalciferol supplementation of 20,000 IU weekly for
Fig. 4 iPTH course after six months of cholecalciferol supplementation in patients with and without (w/o) calcitriol. In patients without calcitriol
iPTH did not change significantly (iPTH post 345 ± 190 vs iPTH pre 316 ± 137 pg/mL). Patients with calcitriol showed a significant iPTH reduction
(336 ± 207 vs 448 ± 238 pg/mL, p = 0.031)
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12- to 13 weeks [44]. Considering the fact that at
present PTH lowering is the only goal for cholecalcif-
erol substitution in dialysis patients, it remains doubtful
whether patients with low PTH levels are candidates
for native vitamin D substitution at all.
One argument against native vitamin D substitution in
dialysis patients has been that most of them already
receive activated vitamin D compounds and therefore
would not profit from additional vitamin D substitution.
Our results, however, suggest that cholecalciferol substi-
tution further decreases PTH in patients already given
low doses of calcitriol. Whether this effect is also present
in patients receiving calcitriol doses above 0.25 μg per
day needs further investigation.
Our study has some limitations and strengths. First, the
number of participants is rather small, but still included
more than twice the number of dialysis patients with cho-
lecalciferol supplementation compared to recently pub-
lished randomized controlled trials [9, 37, 40]. Second, the
study lacks a control group without cholecalciferol substi-
tution, although the retrospective analysis of the 25OHD3
course in the year prior to the cholecalciferol substitution
found no change in 25OHD3 without substitution. We
also did not measure 1,25OHD3 levels, which would have
allowed us to determine whether these levels were associ-
ated with outcomes, especially iPTH levels. In addition,
we also did not measure FGF-23. One major strength of
this study is that treatment with phosphate binders, active
vitamin D compounds and cinacalcet as well as dialysate
calcium was kept strictly constant during the whole treat-
ment period. For this reason, we are sure that the
observed iPTH changes were only a consequence of cho-
lecalciferol substitution.
Conclusion
We found that in dialysis patients with vitamin D defi-
ciency oral substitution with cholecalciferol at a body
weight-adapted dose of 100 IU per kg body weight leads
to a significant increase in 25OHD3 levels close to the
supposed target range of 30 ng/mL. This therapy also
causes a significant drop in iPTH levels, even in patients
with preexisting calcitriol therapy. In addition, it is safe
without causing a rise in serum calcium or phosphorous.
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